[4]https://acrabstracts.org/abstract/cardiovascular-damage-in-systemic-lupus-erythematosus-occurs-at-early-stages-of-the-disease-chronological-analysis-of-damage-accrual-in-a-large-cohort-from-the-spanish-society-of-rheumatology-lupus-r.(2023.11.13) [5]https://acrabstracts.org/abstract/burden-of-...
ACR Convergence 2023, the world’s premier rheumatology experience, will be held November 10–15 at the San Diego Convention Center in San Diego, California. Choose from five options to experience ACR Convergence at your convenience: All Access In Person All Access Online Scientific Sessions In Pe...
近日,美国风湿病学会(ACR)发布指南《2023 American College of Rheumatology (ACR) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease[2023年美国风湿病学会(ACR)关于系统性自身...
近日,美国风湿病学会(ACR)发布指南《2023 American College of Rheumatology (ACR) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease[2023年美国风湿病学会(ACR)关于系统性自...
美国时间11月15日，加州圣地亚哥，美国风湿病学会（ACR,American College of Rheumatology）2023年会现场，荣昌生物制药（烟台）股份有限公司(688331.SH/9995.HK)受邀以口头报告的形式，正式宣布全球首款BLyS/APRIL抑制剂泰它西普（Telitacicept,商品名：泰爱®）治疗类风湿性关节炎（RA）患者的Ⅲ期临床试验，达到...
[12]Unizony S, Matza M A, Jarvie A, et al. Treatment for giant cell arteritis with 8 weeks of prednisone in combination with tocilizumab: a single-arm, open-label, proof-of-concept study[J]. The Lancet Rheumatology, 2023. [13]Dejaco C, Singh Y P, Perel P, et al. 2015 Recommenda...
,美国风湿病学会(ACR,American College of Rheumatology)2023年会现场,荣昌生物制药(烟台)股份有限公司(688331.SH/9995.HK)受邀以口头报告的形式,正式宣布全球首款BLyS/APRIL抑制剂泰它西普(Telitacicept,商品名:泰爱®)治疗类风湿性关节炎(RA)患者的
Conclusion: This clinical practice guideline presents the first recommendations endorsed by the American College of Rheumatology and American College of Chest Physicians for the treatment of ILD in people with SARDs.doi:10.1002/acr.25348Johnson, Sindhu R....
疗效优异!荣昌生物在ACR年会公布泰它西普治疗类风湿关节炎III期结果美国时间11月15日,美国风湿病学会(ACR,American College of Rheumatology)2023年会现场, 荣昌生物制药 (烟台)股份有限公司(688331.SH/9...
2.Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis atAmericanCollege of Rheumatology Convergence Annual Meeting 封面图来源:FiercePharma,就原图有修改 ...